Pomerantz LLP is investigating claims on behalf of investors ofTransocean Ltd.(“Transocean” or the “Company”)(NYSE: RIG).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Transocean and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining […]

— The 50IU, 100IU and 200IU formulations cover aesthetic and therapeutic indicatons — The strong partnership with Medica Group will boost Hugel's expansion in the MENA Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, said on Wednesday it received approval for its botulinum toxin Botulax with aesthetic and therapeutic applications from

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Enphase Energy, Inc. (NASDAQ:ENPH) between April 25, 2023 and October 22, 2024, both dates inclusive (the "Class Period"), of the important February 11, 2025 lead plaintiff deadline. SO

Pomerantz LLP is investigating claims on behalf of investors ofNextracker Inc. (“Nextracker” or the “Company”)(NASDAQ: NXT).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Nextracker and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about

Integris Composites, Inc., a global leader in armor protection for the world's elite military and police, says the new rapid response armor system is a first in an emerging category of Situational Armor. In a departure from a three-decade tradition of producing armor solutions for the world's elite military and law enforcement units, Integris Composites

NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Sun Communities, Inc. (NYSE:SUI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sun-communities-inc-lawsuit-submission-form?prid=124205&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Marqeta, Inc. (NASDAQ:MQ) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marqeta-inc-lawsuit-submission-form?prid=124216&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)

NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=124210&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Dentsply Sirona Inc. (NASDAQ:XRAY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dentsply-lawsuit-submission-form?prid=124208&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=124202&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or